AriBio Co., Ltd. is set to become the first South Korean pharma firm to begin a global Phase III clinical development program for a novel drug for Alzheimer’s disease (AD), following an IND approval from the domestic Ministry of Food and Drug Safety for the Polaris-AD study.
The multinational Phase III trial with the small molecule PDE5 inhibitor AR1001 is set to progress in the US, Europe...
Welcome to Scrip
Create an account to read this article
Already a subscriber?